Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3C3 | Q8NEB9 | 20/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19276352 | 1.00 | PIK3C3 (0.46) | PIK3C3 | |
| SCHEMBL19259449 | 0.89 | PIK3C3 (0.53) | PIK3C3 | |
| SCHEMBL19276422 | 0.89 | PIK3C3 (0.53) | PIK3C3 | |
| SCHEMBL23450331 | 0.86 | PIK3C3 (0.56) | PIK3C3 | |
| SCHEMBL19275770 | 0.86 | PIK3C3 (0.56) | PIK3C3 | |
| SCHEMBL19259521 | 0.86 | PIK3C3 (0.56) | PIK3C3 | |
| SCHEMBL19259424 | 0.86 | PIK3C3 (0.56) | PIK3C3 | |
| SCHEMBL22170329 | 0.85 | PIK3C3 (0.56) | PIK3C3 | |
| SCHEMBL19259425 | 0.85 | PIK3C3 (0.56) | PIK3C3 | |
| SCHEMBL19259477 | 0.84 | PIK3C3 (0.58) | PIK3C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11963963-B2 | 6-heterocyclyl-4-morpholin-4-ylpyridine-2-one compounds useful for the treatment of cancer and diabetes | SPRINT BIOSCIENCE AB (SE) | 2024-04-23 | — | — | US | disclosed |
| US-20230234949-A1 | MORPHOLINYLPYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2023-07-27 | — | — | US | disclosed |
| US-20230234949-A1 | MORPHOLINYLPYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2023-07-27 | — | — | US | disclosed |
| US-20230234949-A1 | MORPHOLINYLPYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2023-07-27 | — | — | US | disclosed |
| CN-116462674-A | Morpholinyl pyridone compounds | 思普瑞特生物科学公司 | 2023-07-21 | — | — | CN | disclosed |
| CN-116444510-A | Morpholinyl pyridone compounds | 思普瑞特生物科学公司 | 2023-07-18 | — | — | CN | disclosed |
| CN-111108102-B | Morpholinyl pyridone compounds | 思普瑞特生物科学公司 | 2023-04-28 | — | — | CN | disclosed |
| US-11560374-B2 | Morpholinylpyridone compounds | SPRINT BIOSCIENCE AB (SE) | 2023-01-24 | — | — | US | disclosed |
| US-11560374-B2 | Morpholinylpyridone compounds | SPRINT BIOSCIENCE AB (SE) | 2023-01-24 | — | — | US | disclosed |
| EP-4056569-A1 | MORPHOLINYLPYRIDONE COMPOUNDS | Sprint Bioscience AB (SE) | 2022-09-14 | — | — | EP | disclosed |
| US-20200361922-A1 | MORPHOLINYLPYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2020-11-19 | — | — | US | disclosed |
| EP-3416957-B1 | 6-HETEROCYCLYL-4-MORPHOLIN-4-YLPYRIDIN-2-ONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETES | SPRINT BIOSCIENCE AB (SE) | 2020-07-01 | — | — | EP | disclosed |
| EP-3672962-A1 | MORPHOLINYLPYRIDONE COMPOUNDS | Sprint Bioscience AB (SE) | 2020-07-01 | — | — | EP | disclosed |
| EP-3416957-B1 | 6-HETEROCYCLYL-4-MORPHOLIN-4-YLPYRIDIN-2-ONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETES | SPRINT BIOSCIENCE AB (SE) | 2020-07-01 | — | — | EP | disclosed |
| CN-111108102-A | Morpholinopyridone compounds | 思普瑞特生物科学公司 | 2020-05-05 | — | — | CN | disclosed |
| WO-2019038390-A1 | MORPHOLINYLPYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2019-02-28 | — | — | WO | disclosed |
| WO-2019038390-A1 | MORPHOLINYLPYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2019-02-28 | — | — | WO | disclosed |
| EP-3416957-A1 | 6-HETEROCYCLYL-4-MORPHOLIN-4-YLPYRIDINE-2-ONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETES | Sprint Bioscience AB (SE) | 2018-12-26 | — | — | EP | disclosed |
| WO-2017140843-A1 | 6-HETEROCYCLYL-4-MORPHOLIN-4-YLPYRIDINE-2-ONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETES | SPRINT BIOSCIENCE AB (SE) | 2017-08-24 | — | — | WO | disclosed |
| WO-2017140843-A1 | 6-HETEROCYCLYL-4-MORPHOLIN-4-YLPYRIDINE-2-ONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETES | SPRINT BIOSCIENCE AB (SE) | 2017-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11560374-B2 | Morpholinylpyridone compounds | MAP1B, RRP12, MYT1 | PIK3C3 3743/4885 |
| US-20200361922-A1 | MORPHOLINYLPYRIDONE COMPOUNDS | MAP1B, RRP12, MYT1 | PIK3C3 3743/4885 |
| US-20230234949-A1 | MORPHOLINYLPYRIDONE COMPOUNDS | MAP1B, RRP12, MYT1 | PIK3C3 3821/4885 |
| US-11963963-B2 | 6-heterocyclyl-4-morpholin-4-ylpyridine-2-one compounds useful for the treatment of cancer and diabetes | CDK6, IL6, CDK4 | PIK3C3 4621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.